Volume 27, Issue 1 (Avicenna Journal of Clinical Medicine-Spring 2020)                   Avicenna J Clin Med 2020, 27(1): 30-36 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alimohammadi S, Sehat F, Porolajal J, Faryadras M. Relationship between Serum Inhibin A and Pregnancy Outcomes. Avicenna J Clin Med 2020; 27 (1) :30-36
URL: http://sjh.umsha.ac.ir/article-1-2032-en.html
1- , feryadresmohammad@gmail.com
Abstract:   (4500 Views)
Background and Objective: Some studies have shown that abnormal levels of biomarkers may be associated with adverse pregnancy outcomes. This study aimed to investigate the association between serum levels of Inhibin A and the outcomes of pregnancy.
Materials and Methods: This retrospective cohort study was conducted on the data obtained from the Inhibin A of 560 pregnant women at 15 to 20 weeks of gestation in Hamadan, Iran. The levels of Inhibin A less than 0.5 and higher than 2 mmol were considered below and high, respectively. The patients were assessed in terms of birth weight, gestational age, Apgar score, preeclampsia, intrauterine fetal death, and cesarean section. The receiver operating characteristic curve level was calculated to detect adverse pregnancy complications. The data were statistically analyzed in STATA software (version 14).
Results: Out of the pregnant women eligible for the study, 33 (5.9%) cases were excluded due to incomplete medical record files and unavailability. Of the remaining 527 patients, 378 (71.7%), 26 (4.9%), and 123 (23.3%) ones had normal, low, had high Inhibin A levels, respectively. Patients with higher serum Inhibin A levels had a higher risk of preeclampsia, low birth weight, and prematurity, compared to those with normal or low levels (P˂0.05).
Conclusion: Based on the findings of the present study, high levels of Inhibin A at 15 to 20 weeks of gestation can be associated with the risk of preeclampsia, low birth weight, and prematurity.
 
Full-Text [PDF 866 kb]   (1411 Downloads)    
Type of Study: Original | Subject: Obstetrics & Gynecology

References
1. Cochrane L, Brumpton K, Winter S, Bell K, Burnham H, Wadwell K, et al. Prevalence and outcomes of overweight and obesity among pregnant women in rural Queensland. Aust J Rural Health. 2019;27(2):164-9. PMID: 30950131 DOI: 10.1111/ajr.12495
2. Lockwood G, Ledger W, Barlow D, Groome N, Muttukrishna S. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod. 1997;57(6):1490-4. PMID: 9408259 DOI: 10.1095/biolreprod57.6.1490
3. Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Exp Biol Med. 2007;232(8):993-1004. PMID: 17720945 DOI: 10.3181/0612-MR-291
4. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem. 1997;272(21):13835-42. PMID: 9153241 DOI: 10.1074/jbc.272.21.13835
5. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update. 2002;8(6):529-41. PMID: 12498423 DOI: 10.1093/humupd/8.6.529
6. Gagnon A, Wilson RD. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918-32. PMID: 19038077 DOI: 10.1016/S1701-2163(16)32973-5
7. Jelliffe-Pawlowski LL, Shaw GM, Currier RJ, Stevenson DK, Baer RJ, O'Brodovich HM, et al. Association of early-preterm birth with abnormal levels of routinely collected first-and second-trimester biomarkers. Am J Obstet Gynecol. 2013;208(6):492.e1-11. PMID: 23395922 DOI: 10.1016/j.ajog.2013.02.012
8. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:194-201. PMID: 25305662 DOI: 10.1016/j.ejogrb.2014.09.027
9. Broumand F, Lak SS, Nemati F, Mazidi A. A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women. Electron Physician. 2018;10(1):6186-92. PMID: 29588818 DOI: 10.19082/6186
10. Singnoi W, Wanapirak C, Sekararithi R, Tongsong T. A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study. BMC Pregnancy Childbirth. 2019;19(1):124. PMID: 30971214 DOI: 10.1186/s12884-019-2266-y
11. Lentz EJ, Park AL, Langlois AW, Huang T, Meschino WS, Ray JG. Risk of severe maternal morbidity or death in relation to prenatal biochemical screening: population-based cohort study. Am J Perinatol. 2019;14:333. PMID: 31412403 DOI: 10.1055/s-0039-1694731
12. Lambert-Messerlian GM, Silver HM, Petraglia F, Luisi S, Pezzani I, Maybruck WM, et al. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy. J Soc Gynecol Investig. 2000;7(3):170-4. PMID: 10865185 DOI: 10.1016/s1071-5576(00)00050-2
13. Muttukrishna S, Hyett J, Paine M, Moodley J, Groome N, Rodeck C. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol (Oxf). 2006;64(4):469-73. PMID: 16584522 DOI: 10.1111/j.1365-2265.2006.02476.x
14. Silver HM, Lambert-Messerlian GM, Reis FM, Diblasio AM, Petraglia F, Canick JA. Mechanism of increased maternal serum total activin a and inhibin a in preeclampsia. J Soc Gynecol Investig. 2002;9(5):308-12. PMID: 12383916 DOI: 10.1016/s1071-5576(02)00165-x
15. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-99. PMID: 15733721 DOI: 10.1016/S0140-6736(05)17987-2
16. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44. PMID: 20598363 DOI: 10.1016/S0140-6736(10)60279-6
17. Fitzgerald B, Levytska K, Kingdom J, Walker M, Baczyk D, Keating S. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011;32(4):339-45. PMID: 21388678 DOI: 10.1016/j.placenta.2011.01.018

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb